Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaston, Czar Louie, Grimer, Robert J., Parry, Michael, Stacchiotti, Silvia, Dei Tos, Angelo Paolo, Gelderblom, Hans, Ferrari, Stefano, Baldi, Giacomo G., Jones, Robin L., Chawla, Sant, Casali, Paolo, LeCesne, Axel, Blay, Jean-Yves, Dijkstra, Sander P. D., Thomas, David M., Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022265/
https://www.ncbi.nlm.nih.gov/pubmed/27651889
http://dx.doi.org/10.1186/s13569-016-0056-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022265/
https://www.ncbi.nlm.nih.gov/pubmed/27651889
http://dx.doi.org/10.1186/s13569-016-0056-0

Ejemplares similares